BCM
AMRX icon

BlueCrest Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

BlueCrest Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-22,345
Closed -$65K – 394
2019
Q3 		$65K Buy
+22,345
New +$78K ﹤0.01% 547

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlueCrest Capital Management's AMRX Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q4 2019, closing a stake of 22,345 shares — an estimated $65K sold.

BlueCrest Capital Management first reported a position in AMRX in Q3 2019 and held it in 1 quarter. The position peaked at $65K in Q3 2019. 129 funds tracked by Wall St. Rank hold AMRX as of Q4 2019.

  • BlueCrest Capital Management reported no remaining Amneal Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 22,345 Amneal Pharmaceuticals shares in Q4 2019, an estimated $65K.
  • BlueCrest Capital Management first reported a position in Amneal Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Amneal Pharmaceuticals position peaked at $65K in Q3 2019.
  • 129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.